COLO-B.CO

ACCE thesis

Coloplast manufactures ostomy bags, urological catheters, and wound care products for patients with chronic conditions requiring long-term medical devices. The company owns 40% of the global ostomy market and benefits from an aging population that drives steady 4-6% annual volume growth across its core categories. Management expects the chronic care division to accelerate growth through new product launches in 2024, including advanced adhesive technologies that extend wear time for ostomy patients. Trading at 22x forward earnings with 15% operating margins, Coloplast offers defensive healthcare exposure with predictable recurring revenue from patients who use these products for life. The stock has dropped 18% this year despite maintaining mid-single-digit organic growth, creating an entry point into Europe's most profitable medical device franchise.

• high
  Revenue growth stagnation

  Revenue growth collapsed to +0.2% YoY from 5-year CAGR of +7.3%, indicating significant deceleration.
• high
  High debt burden

  Debt/Equity ratio of 181.80 represents extremely high leverage that could constrain financial flexibility.
• moderate
  ACCE score decline

  Overall ACCE score of 66/100 with particularly weak Growth score of 55 suggests deteriorating fundamentals.

Snapshot